J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes
This article was originally published in The Gray Sheet
Executive Summary
Abbott could be a strong player in the drug-eluting stent market by 2007 if the J&J/Guidant merger is completed as required by FTC
You may also be interested in...
Zoll’s AutoPulse CPR-Assist Device Helps Resuscitate Stock, Up 24% In Q2
Zoll Medical's accelerating revenue growth, driven in part by strong sales of its AutoPulse CPR-assist device, helped fuel a 24.4% jump in the firm's stock price in the second quarter
Zoll’s AutoPulse CPR-Assist Device Helps Resuscitate Stock, Up 24% In Q2
Zoll Medical's accelerating revenue growth, driven in part by strong sales of its AutoPulse CPR-assist device, helped fuel a 24.4% jump in the firm's stock price in the second quarter
Guidant Accepts Yet Another J&J Bid As Takeover War Escalates
Guidant accepted an increased takeover bid by Johnson & Johnson late Jan. 13, leaving Boston Scientific to once again weigh whether to continue its bidding war with J&J